Aline Fares
@AlineFaresMD
Followers
464
Following
3K
Media
14
Statuses
452
Medical Oncologist at University of Florida @UFHealthCancer DSG Thoracic Research Lead. Former @pmcancercentre @acccancercenter #lungcancer
Gainesville, FL
Joined May 2019
Big congratulations to @KHigginsMD on becoming the new Chair of the NRG Lung Cancer Committee! š.Grateful for the incredible leadership of Dr. Jeff Bradley (2013ā2025), whose dedication advanced lung cancer research in countless ways #lcsm #lungcancer @NRGonc @NRGOncology.
0
0
1
0
1
0
Excited about all the Phase 3 trials and IITs launching in our UF Thoracic Oncology portfolio! Grateful to be part of a team pushing research forward for our lung cancer patients. šš« #lcsm #LungCancer #ClinicalTrials @TGeorgeMD.
1
1
10
Though I had the chance to work w Dr. Das for only a few months at UF, I learned so much from her dedication, leadership,passion for lung cancer care. Wishing her all the best as she takes on a new role as Head of MedOnc - next team is lucky to have her! Will miss u @DevikaDasMD.
1
0
11
RT @UFHealthCancer: Congratulations to UF Health Cancer Center members Drs. Araujo, Fares, Gim and Nicholson, who were selected as membersā¦.
0
2
0
RT @DrJNaidoo: Sherlock-Lung: Mutagenesis of LC in Never Smokers (LCNS) ā¦ā¦@Natureā©:.- 871pt samples.- KRAS+ ā¬ļø3.8x in LCNSās in USA/EU v Asā¦.
nature.com
Nature - An analysis of data from the Sherlock-Lung study provides insight into the mutational processes that contribute to lung cancer in never smokers, and looks at the possible role of factors...
0
24
0
DiscussĆ£o bem legal!.
How is EGFR-mutant #NSCLC managed in Brazil? In this episode of #LungCancerConsidered, @clarissamathias moderates a discussion with @HaradaGuilherme and Dr. William N. William in Portuguese on treatment approaches for EGFR+ NSCLC. š§ Listen now:
0
0
0
RT @Annals_Oncology: š article in press: Identifying the genomic landscape of EGFR-mutant lung cancers with CNS metastases .
0
7
0
RT @Dr_ElvinaA: Proud to share our review in Cancer Treatment Reviews:.We explore how trial designs are evolving to prioritize safety, biomā¦.
0
21
0
RT @PTarantinoMD: ADCs: are we dosing them right? Likely not. In this body composition study of 48 patients with mBC receiving T-DXd, higheā¦.
0
65
0
RT @StephenVLiu: Real world outcomes for #EGFR NSCLC with 1L osimertinib @JTOonline from ConcertAI, Flatiron Clinical-Genomics, and COTA daā¦.
jto.org
Patients with NSCLC harboring EGFR mutations (EGFRm) have high mortality. The third-generation tyrosine kinase inhibitor, osimertinib, is approved for first-line EGFRm NSCLC. We used longitudinal...
0
23
0
RT @vincentlamMD: Always a tall task to debate @bensolomon1, but @ShirishGadgeel and I make the case for personalizing TKI choice in the CRā¦.
0
11
0
RT @zalaly: 1. What are the benefits and risks of GLP1?. Our new study in @naturemedicine comprehensively maps all the benefits and risks oā¦.
nature.com
Nature Medicine - An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other...
0
305
0
RT @ipreeshagul: ā°ATTENTION ā° . Patients w/ Lung Cancer . āFrustrated by common clinical trial barriers ie: .-long visits &ā³away from familā¦.
0
8
0
RT @LuisRaezMD: Very good review of KRASg12c and others, despite the fact we have drugs for g12c resistance arises soon, we have now PAN KRā¦.
0
9
0
RT @CharlesSwanton: Our paper describing the use of an ultrasensitive circulating tumour DNA detection assay to stratify #TRACERx patientsā¦.
0
80
0
